• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Lung cancer - Articles and news items

stancell-scib2-lung-cancer

Scancell preparing SCIB2 for clinical study in lung cancer

Industry news / 13 October 2016 / Niamh Louise Marriott, Digital Content Producer

Scancell intends to develop its SCIB2 ImmunoBody for the treatment of non-small cell lung cancer (NSCLC) in combination with a checkpoint inhibitor…

approval-pfizer-lung-cancer

EU approval for Pfizer’s non-small cell lung cancer drug

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

The drug exhibited marked anti-tumour activity in patients with ROS1-positive advanced NSCLC and met its primary endpoint of ORR. Tumours were tested for ROS1 rearrangements by laboratory-developed break-apart fluorescence in situ hybridization (FISH) (96%) or real-time polymerase chain reaction (RT-PCR) (4%) assay…

Crizotinib lung cancer price drop

NICE recommends Pfizer’s lung cancer drug after price drop

Industry news / 18 August 2016 / The National Institute for Health and Care Excellence (NICE)

When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value for money on the NHS…

broken pill cancer

Unsuccessful and disappointing clinical trials for AstraZeneca’s lung cancer drug

Industry news / 9 August 2016 / AstraZeneca

The results showed that the trial did not meet its primary endpoint of progression-free survival (PFS), and selumetinib did not have a significant effect on overall survival (OS). The adverse event profiles for selumetinib and docetaxel were consistent with those seen previously…

PharmaMar initiates a phase III ATLANTIS study in patients with small cell lung cancer

PharmaMar initiates a phase III ATLANTIS study for small cell lung cancer

Industry news / 2 August 2016 / PharmaMar

PharmaMar announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 (lurbinectedin) in combination with doxorubicin versus topotecan or the combination VCR (cyclophosphamide, adriamicine (doxorubicin) and vincristine) in patients with small cell lung cancer after the failure of one prior platinum-containing line.

keytruda

CHMP positive opinion for Keytruda in NSCLC

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

The CHMP has recommended approval of Keytruda for the treatment of locally advanced or metastatic NSCLC in adults whose tumours express PD-L1…

savolitinib

Expanded Phase II trial of savolitinib in NSCLC starts

Industry news / 20 June 2016 / Victoria White, Digital Content Producer

Savolitinib is a potential global first-in-class inhibitor of c-Met, an enzyme which has been shown to function abnormally in many types of solid tumours…

KEYNOTE-024

Keytruda superior to chemotherapy in NSCLC study

Industry news / 17 June 2016 / Victoria White, Digital Content Producer

The KEYNOTE-024 trial investigating Keytruda in patients with previously untreated advanced non-small cell lung cancer has met its primary endpoint…

avastin

EC approves Avastin plus Tarceva in NSCLC

Industry news / 8 June 2016 / Victoria White, Digital Content Producer

The combination is approved for the first-line treatment of adult patients with non-squamous NSCLC with EGFR-activating mutations…

PharmaMar initiates a phase III ATLANTIS study in patients with small cell lung cancer

BMS and MD Anderson in lung cancer research collaboration

Industry news / 7 June 2016 / Victoria White, Digital Content Producer

BMS and MD Anderson are to collaborate to evaluate innovative strategies for the use of Opdivo and Yervoy to treat lung cancer patients…

tafinlar

Novartis presents new data for Tafinlar + Mekinist at ASCO

Industry news / 7 June 2016 / Victoria White, Digital Content Producer

Novartis has announced new data for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in non-small cell lung cancer (NSCLC) and melanoma…

nsclc

Data for Alimta and Cyramza plus keytruda in NSCLC presented at ASCO

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Data were presented from two early-phase trials evaluating Lilly’s Alimta and Cyramza in combination with Merck’s Keytruda in patients with NSCLC…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +